Showing results (21-30 of 132) with videos related to

Sort By:
Pageof 14
Future Oncology (London, England)|July 19, 2021
Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for <i>EGFR</i>-mutated resectable non-small-cell lung cancer: NeoADAURAMasahiro Tsuboi, Walter Weder, Carles Escriu, et al.
Lung Cancer (Amsterdam, Netherlands)|November 13, 2015
HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinibBob T Li, Adrian Lee, Sandra O'Toole, et al.
Annals of Translational Medicine|December 30, 2017
Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancersBob T Li, Dennis Stephens, Jamie E Chaft, et al.
Molecular Cancer Therapeutics|February 2, 2013
EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristicsMaria E Arcila, Khedoudja Nafa, Jamie E Chaft, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomasJuliana B Schilsky, Ai Ni, Linda Ahn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 3, 2016
HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung CancersBob T Li, Dara S Ross, Dara L Aisner, et al.
JNCI Cancer Spectrum|March 23, 2024
Pathological response in resectable non-small cell lung cancer: a systematic literature review and meta-analysisNathalie A Waser, Melanie Quintana, Bernd Schweikert, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 2, 2019
Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancerNarek Shaverdian, Michael D Offin, Andreas Rimner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 4, 2015
Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung AdenocarcinomasJuliana Eng, Kaitlin M Woo, Camelia S Sima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2012
Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomasMaria E Arcila, Jamie E Chaft, Khedoudja Nafa, et al.
Pageof 14